RA
WST icon

Rise Advisors’s West Pharmaceutical WST Stock Holding History

Rise Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80
Closed -$21.1K – 1443
2025
Q3 		$21.1K Hold
80
– – 0.01% 542
2025
Q2 		$17.5K Hold
80
– – 0.01% 611
2025
Q1 		$17.9K Buy
80
+28
+54% +$7.72K 0.01% 564
2024
Q4 		$17.1K Buy
52
+2
+4% +$629 0.01% 758
2024
Q3 		$15K Hold
50
– – 0.01% 863
2024
Q2 		$16.5K Hold
50
– – 0.01% 769
2024
Q1 		$19.8K Buy
+50
New +$18.5K 0.01% 657
2023
Q2 		– Sell
-26
Closed -$9.05K – 805
2023
Q1 		$9.05K Hold
26
– – 0.01% 377
2022
Q4 		$6.14K Hold
26
– – ﹤0.01% 418
2022
Q3 		$6K Hold
26
– – 0.01% 425
2022
Q2 		$8K Hold
26
– – 0.01% 383
2022
Q1 		$11K Hold
26
– – 0.01% 319
2021
Q4 		$12.2K Buy
+26
New +$11.2K 0.01% 301

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rise Advisors's WST Position: Q4 2025 in Review

Rise Advisors sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 80 shares — an estimated $21.1K sold.

Rise Advisors first reported a position in WST in Q4 2021 and held it in 13 quarters. The position peaked at $21.1K in Q3 2025. 804 funds tracked by Wall St. Rank hold WST as of Q4 2025.

  • Rise Advisors reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 80 West Pharmaceutical shares in Q4 2025, an estimated $21.1K.
  • Rise Advisors first reported a position in West Pharmaceutical in Q4 2021 and held it in 13 quarters.
  • Rise Advisors's West Pharmaceutical position peaked at $21.1K in Q3 2025.
  • 804 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.